British Journal of Cancer - Table of Contents alert Volume 115 Issue 10

If you are unable to see the message below, click here to view.

TABLE OF CONTENTS Volume 115, Issue 10 (1157-1272) Published online 8 November 2016 In this issue Review Clinical Studies Translational Therapeutics Molecular Diagnostics Also new today Advance online publication Digital Edition Sign up for e-alerts Recommend to your library Web feed Subscribe Review Top PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions G E Konecny and R S Kristeleit Br J Cancer 2016 115: 1157-1173; advance online publication, October 13, 2016; 10.1038/bjc.2016.311 Abstract | Full Text Clinical Studies Top Outcome of ovarian cancer after breast cancer in BRCA1 and BRCA2 mutation carriers Leendert H Zaaijer, Helena C van Doorn, Marian J E Mourits, Marc van Beurden, Joanne A de Hullu, Muriel A Adank, Luc R C W van Lonkhuijzen, Hans F A Vasen, Brigitte F M Slangen, Katja N Gaarenstroom, Ronald P Zweemer, Peggy M L H Vencken, Caroline Seynaeve and Mieke Kriege Br J Cancer 2016 115: 1174-1178; advance online publication, October 18, 2016; 10.1038/bjc.2016.333 Abstract | Full Text Patients’ and clinicians’ preferences for adjuvant chemotherapy in endometrial cancer: an ANZGOG substudy of the PORTEC-3 intergroup randomised trial On behalf of the ANZGOG and PORTEC Group, Prunella Blinman, Linda Mileshkin, Pearly Khaw, Geraldine Goss, Carol Johnson, Anne Capp, Susan Brooks, Gerard Wain, Ilka Kolodziej, Anne-Sophie Veillard, Rachel O'Connell, Carien L Creutzberg and Martin R Stockler Br J Cancer 2016 115: 1179-1185; advance online publication, October 20, 2016; 10.1038/bjc.2016.323 Abstract | Full Text Patterns of response to anti-PD-1 treatment: an exploratory comparison of four radiological response criteria and associations with overall survival in metastatic melanoma patients Leila Khoja, Minnie Kibiro, Ur Metser, Craig Gedye, David Hogg, Marcus O Butler, Eshetu G Atenafu and Anthony M Joshua Br J Cancer 2016 115: 1186-1192; advance online publication, October 4, 2016; 10.1038/bjc.2016.308 Abstract | Full Text RADVAN: a randomised phase 2 trial of WBRT plus vandetanib for melanoma brain metastases – results and lessons learnt Avinash Gupta, Corran Roberts, Finn Tysoe, Matthew Goff, Jenny Nobes, James Lester, Ernie Marshall, Carie Corner, Virginia Wolstenholme, Charles Kelly, Adelyn Wise, Linda Collins, Sharon Love, Martha Woodward, Amanda Salisbury and Mark R Middleton Br J Cancer 2016 115: 1193-1200; advance online publication, October 6, 2016; 10.1038/bjc.2016.318 Abstract | Full Text TTP as a surrogate endpoint in advanced hepatocellular carcinoma treated with molecular targeted therapy: meta-analysis of randomised controlled trials Dae-Won Lee, Myoung-Jin Jang, Kyung-Hun Lee, Eun Ju Cho, Jeong-Hoon Lee, Su Jong Yu, Yoon Jun Kim, Jung-Hwan Yoon, Tae-Yong Kim, Sae-Won Han, Do-Youn Oh, Seock-Ah Im and Tae-You Kim Br J Cancer 2016 115: 1201-1205; advance online publication, October 13, 2016; 10.1038/bjc.2016.322 Abstract | Full Text A phase 3 trial evaluating panitumumab plus best supportive care vs best supportive care in chemorefractory wild-type KRAS or RAS metastatic colorectal cancer Tae Won Kim, Anneli Elme, Zvonko Kusic, Joon Oh Park, Anghel Adrian Udrea, Sun Young Kim, Joong Bae Ahn, Ricardo Villalobos Valencia, Srinivasan Krishnan, Ante Bilic, Nebojsa Manojlovic, Jun Dong, Xuesong Guan, Catherine Lofton-Day, A Scott Jung and Eduard Vrdoljak Br J Cancer 2016 115: 1206-1214; advance online publication, October 13, 2016; 10.1038/bjc.2016.309 Abstract | Full Text Impact of tumour RAS/BRAF status in a first-line study of panitumumab + FOLFIRI in patients with metastatic colorectal cancer Meinolf Karthaus, Ralf-Dieter Hofheinz, Laurent Mineur, Henry Letocha, Richard Greil, Josef Thaler, Eva Fernebro, Kelly S Oliner, Michael Boedigheimer, Brian Twomey, Ying Zhang, Gaston Demonty and Claus-Henning Köhne Br J Cancer 2016 115: 1215-1222; advance online publication, October 20, 2016; 10.1038/bjc.2016.343 Abstract | Full Text Translational Therapeutics Top FOXO3a and the MAPK p38 are activated by cetuximab to induce cell death and inhibit cell proliferation and their expression predicts cetuximab efficacy in colorectal cancer L Marzi, E Combes, N Vié, A Ayrolles-Torro, D Tosi, D Desigaud, E Perez-Gracia, C Larbouret, C Montagut, M Iglesias, M Jarlier, V Denis, L K Linares, E W-F Lam, P Martineau, M Del Rio and C Gongora Br J Cancer 2016 115: 1223-1233; advance online publication, September 29, 2016; 10.1038/bjc.2016.313 Abstract | Full Text IL-6 controls resistance to radiation by suppressing oxidative stress via the Nrf2-antioxidant pathway in oral squamous cell carcinoma Yuichiro Matsuoka, Hideki Nakayama, Ryoji Yoshida, Akiyuki Hirosue, Masashi Nagata, Takuya Tanaka, Kenta Kawahara, Junki Sakata, Hidetaka Arita, Hikaru Nakashima, Satoru Shinriki, Daiki Fukuma, Hidenao Ogi, Akimitsu Hiraki, Masanori Shinohara, Ryo Toya and Ryuji Murakami Br J Cancer 2016 115: 1234-1244; advance online publication, October 13, 2016; 10.1038/bjc.2016.327 Abstract | Full Text Molecular Diagnostics Top DLL4 expression is a prognostic marker and may predict gemcitabine benefit in resected pancreatic cancer A Drouillard, F Puleo, J B Bachet, S Ouazzani, A Calomme, P Demetter, G Verset, J L Van Laethem and R Maréchal Br J Cancer 2016 115: 1245-1252; advance online publication, October 18, 2016; 10.1038/bjc.2016.319 Abstract | Full Text Co-targeting of FAK and MDM2 triggers additive anti-proliferative effects in mesothelioma via a coordinated reactivation of p53 Wen-Bin Ou, Minmin Lu, Grant Eilers, Hailong Li, Jiongyan Ding, Xuli Meng, Yuehong Wu, Quan He, Qing Sheng, Hai-Meng Zhou and Jonathan A Fletcher Br J Cancer 2016 115: 1253-1263; advance online publication, October 13, 2016; 10.1038/bjc.2016.331 Abstract | Full Text NCCN-IPI score-independent prognostic potential of pretreatment uric acid levels for clinical outcome of diffuse large B-cell lymphoma patients Katharina T Prochazka, Thomas Melchardt, Florian Posch, Konstantin Schlick, Alexander Deutsch, Christine Beham-Schmid, Lukas Weiss, Thomas Gary, Daniel Neureiter, Eckhard Klieser, Richard Greil, Peter Neumeister, Alexander Egle and Martin Pichler Br J Cancer 2016 115: 1264-1272; advance online publication, October 20, 2016; 10.1038/bjc.2016.325 Abstract | Full Text Please note that you need to be a subscriber or site-licence holder to enjoy full-text access to British Journal of Cancer. In order to do so, please purchase a subscription. You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/nams/svc/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department. For print subscription enquiries, please contact our subscription department. For other enquiries, please contact our customer feedback department. Nature Publishing Group |One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at The Campus, 4 Crinan Street, London, N1 9XW. © 2016 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.